{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:50:56Z","timestamp":1793901056796,"version":"4.8.0"},"reference-count":25,"publisher":"American Association for Cancer Research (AACR)","issue":"4","funder":[{"DOI":"10.13039\/100005895","name":"Fred Hutchinson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005895","id-type":"DOI","asserted-by":"publisher"}]},{"name":"David and Patricia Giuliani Family Foundation"},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA015704"],"award-info":[{"award-number":["P30 CA015704"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell therapy produces high response rates in refractory B-cell non\u2013Hodgkin lymphoma, but long-term data are minimal to date. In this study, we present long-term follow-up of a pilot trial testing a CD20-targeting third-generation CAR in patients with relapsed B-cell lymphomas following cyclophosphamide-only lymphodepletion. Two of the three patients in the trial, with mantle cell lymphoma and follicular lymphoma, had remissions lasting more than 7 years, though they ultimately relapsed. The absence of B-cell aplasia in both patients suggested a lack of functional CAR T-cell persistence, leading to the hypothesis that endogenous immune responses were responsible for these long-term remissions. Correlative immunologic analyses supported this hypothesis, with evidence of new humoral and cellular antitumor immune responses proximal to clinical response time points. Collectively, our results suggest that CAR T-cell therapy may facilitate epitope spreading and endogenous immune response formation in lymphomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Two of three patients treated with CD20-targeted CAR T-cell therapy had long-term remissions, with evidence of endogenous antitumor immune response formation. Further investigation is warranted to develop conditions that promote epitope spreading in lymphomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-23-0263","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T08:04:07Z","timestamp":1715760247000},"page":"258-266","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor\u2013Adoptive T-cell Therapy"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9535-778X","authenticated-orcid":false,"given":"George","family":"Mo","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6938-3781","authenticated-orcid":false,"given":"Sang Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Translational Science and Therapeutics Division, Seattle, Washington. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3544-8836","authenticated-orcid":false,"given":"David G.","family":"Coffey","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington. 1"},{"name":"University of Miami, Miami, Florida. 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5751-3881","authenticated-orcid":false,"given":"Valentin","family":"Voillet","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, Washington. 4"},{"name":"Cape Town HVTN Immunology Laboratory, Hutchinson Centre Research Institute of South Africa, Cape Town, South Africa. 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5592-5201","authenticated-orcid":false,"given":"Ilan R.","family":"Kirsch","sequence":"additional","affiliation":[{"name":"Adaptive Biotechnologies, Seattle, Washington. 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3867-0232","authenticated-orcid":false,"given":"Raphael","family":"Gottardo","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, Washington. 4"},{"name":"University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland. 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2329-8298","authenticated-orcid":false,"given":"Kimberly S.","family":"Smythe","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Translational Science and Therapeutics Division, Seattle, Washington. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6799-2022","authenticated-orcid":false,"given":"Cecilia C.S.","family":"Yeung","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Translational Science and Therapeutics Division, Seattle, Washington. 2"},{"name":"Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington. 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1634-4743","authenticated-orcid":false,"given":"Adam","family":"Greenbaum","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Translational Science and Therapeutics Division, Seattle, Washington. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0477-1446","authenticated-orcid":false,"given":"Damian J.","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington. 1"},{"name":"Fred Hutchinson Cancer Center, Translational Science and Therapeutics Division, Seattle, Washington. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8477-6919","authenticated-orcid":false,"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington. 1"},{"name":"Fred Hutchinson Cancer Center, Translational Science and Therapeutics Division, Seattle, Washington. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4718-8288","authenticated-orcid":false,"given":"Brian G.","family":"Till","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, Washington. 1"},{"name":"Fred Hutchinson Cancer Center, Translational Science and Therapeutics Division, Seattle, Washington. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"2026041310134998600_bib1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2026041310134998600_bib2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026041310134998600_bib3","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026041310134998600_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026041310134998600_bib5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"2026041310134998600_bib6","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2026041310134998600_bib7","doi-asserted-by":"crossref","first-page":"e134612","DOI":"10.1172\/jci.insight.134612","article-title":"Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy","volume":"5","author":"Chen","year":"2020","journal-title":"JCI Insight"},{"key":"2026041310134998600_bib8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","article-title":"Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity","volume":"21","author":"Lai","year":"2020","journal-title":"Nat Immunol"},{"key":"2026041310134998600_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2026041310134998600_bib10","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"key":"2026041310134998600_bib11","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","article-title":"Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1","volume":"358","author":"Hunder","year":"2008","journal-title":"N Engl J Med"},{"key":"2026041310134998600_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","article-title":"CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response","volume":"35","author":"Kuhn","year":"2019","journal-title":"Cancer Cell"},{"key":"2026041310134998600_bib13","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"key":"2026041310134998600_bib14","unstructured":"Coffey\n              D\n            \n          . LymphoSeqDB: LymphoSeq annotation databases. R package Version 099.2. 2016. Available from:https:\/\/bioconductor.org\/packages\/release\/data\/annotation\/html\/LymphoSeqDB.html."},{"key":"2026041310134998600_bib15","unstructured":"Hu\n              H-M\n            , PaustianCC, WenZ, MoudgilTL, HiltonTL, BookhardtS, . Single cell sequencing to identify TCRs that recognize autologous tumor cells after vaccination with allogeinic DRibble vaccine. 2018. Available from:https:\/\/digitalcommons.providence.org\/sitc2018\/2\/."},{"key":"2026041310134998600_bib16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.4049\/jimmunol.1801401","article-title":"Antigen-specific TCR signatures of cytomegalovirus infection","volume":"202","author":"Huth","year":"2019","journal-title":"J Immunol"},{"key":"2026041310134998600_bib17","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1084\/jem.20092140","article-title":"Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens","volume":"207","author":"Jongbloed","year":"2010","journal-title":"J Exp Med"},{"key":"2026041310134998600_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2141.2012.09123.x","article-title":"A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential","volume":"158","author":"Lee","year":"2012","journal-title":"Br J Haematol"},{"key":"2026041310134998600_bib19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3109\/10428194.2011.562570","article-title":"Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma","volume":"52","author":"Jung","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"2026041310134998600_bib20","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026041310134998600_bib21","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1084\/jem.20152021","article-title":"Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient","volume":"213","author":"Chapuis","year":"2016","journal-title":"J Exp Med"},{"key":"2026041310134998600_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.omto.2017.12.003","article-title":"CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity","volume":"8","author":"Kueberuwa","year":"2018","journal-title":"Mol Ther Oncolytics"},{"key":"2026041310134998600_bib23","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1038\/ncomms3680","article-title":"Using synthetic templates to design an unbiased multiplex PCR assay","volume":"4","author":"Carlson","year":"2013","journal-title":"Nat Commun"},{"key":"2026041310134998600_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jim.2011.09.001","article-title":"Ultra-sensitive detection of rare T cell clones","volume":"375","author":"Robins","year":"2012","journal-title":"J Immunol Methods"},{"key":"2026041310134998600_bib25","unstructured":"Coffey\n              D\n            \n          . LymphoSeq: analyze high-throughput sequencing of T and B cell receptors. R package version 1.30. Available from:https:\/\/bioconductor.org\/packages\/LymphoSeq."}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0263\/3453457\/bcd-23-0263.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0263\/3460930\/bcd-23-0263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/4\/258\/3470406\/bcd-23-0263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/4\/258\/3470406\/bcd-23-0263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:14:03Z","timestamp":1776089643000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/5\/4\/258\/746107\/Long-term-Remissions-Following-CD20-Directed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,5,10]]},"published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-23-0263","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.26134249","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134237","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134249.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134246.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134246","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32696169","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134240","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134243","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134237.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32696166","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32696178","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32696172","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134240.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.32696175","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134243.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.7309423.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.7309423","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,10]]}}}